Shots:

• The US FDA has cleared an IND application to initiate P-Ib/II (SHIELD-2) to evaluate the safety, tolerability & preliminary efficacy of elzovantinib (MET inhibitor) + EQRx’s aumolertinib in patients with EGFR mutant MET-amplified NSCLC. The trial is expected to initiate in mid-2022
• In preclinical data, the combination therapy has the potential to increase anti-tumor activity based on complementary mechanisms while 15 to 20% has developed MET amplification who progress on a 1L EGFR inhibitor develop MET amplification based on acquired resistance
• Aumolertinib is an EGFR inhibitor & was approved in China for 1L treatment of EGFR mutant NSCLC & 2L treatment of T790M+ EGFR mutant NSCLC

Ref: Globe Newswire | Image: Businesswire